Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544086 | 0.86 | SMN1; SMN2 (0.52) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL23440 | 0.86 | AOC3 (0.40) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL25434306 | 0.85 | CA1 (0.61) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL151213 | 0.85 | CA1 (0.61) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL27753904 | 0.85 | CA1 (0.61) | SMN1; SMN2CA12CA1CA2CA4 | |
| Bromide SCHEMBL28158222 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2CA12CA1CA2CA4 | |
| Ammonia Solution, Strong SCHEMBL4268652 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL27731704 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2CA12CA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL31658961 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2CA12CA1CA2CA4 | |
| SCHEMBL14120688 | 0.83 | CA12 (0.37) | SMN1; SMN2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12402529-B2 | Organic compound, composition, organic optoelectronic device, and display device | SAMSUNG SDI CO., LTD. (KR) | 2025-08-26 | — | — | US | disclosed |
| WO-2024122460-A1 | RESIST COMPOSITION AND METHOD FOR PRODUCING SAME | 株式会社日本触媒 | 2024-06-13 | — | — | WO | disclosed |
| US-11844271-B2 | Organic compound, composition, organic optoelectronic device, and display apparatus | SAMSUNG SDI CO., LTD. (KR) | 2023-12-12 | — | — | US | disclosed |
| US-20230371371-A1 | ORGANIC COMPOUND, COMPOSITION, ORGANIC OPTOELECTRONIC DEVICE, AND DISPLAY DEVICE | SAMSUNG SDI CO LTD (KR) | 2023-11-16 | — | — | US | disclosed |
| US-20200388765-A1 | ORGANIC COMPOUND, COMPOSITION, ORGANIC OPTOELECTRONIC DEVICE, AND DISPLAY APPARATUS | SAMSUNG SDI CO., LTD. (KR) | 2020-12-10 | — | — | US | disclosed |
| US-10553800-B2 | Condensed cyclic compound and an organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-02-04 | — | — | US | disclosed |
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2019-04-02 | — | — | US | disclosed |
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-02-22 | — | — | US | disclosed |
| CN-107428744-A | Novel heterocyclic compounds and its application in medicine and cosmetics | 盖尔德马研究及发展公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-104870445-B | New dihydro-pyrimidin and isobioquin group and its pharmaceutical composition (GPR84 antagonists) for treating inflammatory disease | 加拉帕戈斯股份有限公司 | 2017-09-15 | — | — | CN | disclosed |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | WYETH (US) | 2006-10-26 | — | — | US | disclosed |
| US-7119205-B2 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | ABBOTT LABORATORIES (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060100218-A1 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PLEXXIKON, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006026754-A9 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON INC (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006026754-A2 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1532113-A2 | SUBSTITUTED HIHYDROQUINOLINES AS GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-6858627-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20050038068-A1 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | ABBVIE INC. | 2005-02-17 | — | — | US | disclosed |
| US-20040116455-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004018429-A2 | SUBSTITUTED HIHYDROQUINOLINES AS GLUCOCORTICOID MIMETICS, METHODS OF MAKING THEM, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100218-A1 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PDE4B, PDE4A, PDE4C | SMN1; SMN2 3115/4885CA12 3109/4885CA1 383/4885 |
| US-20230371371-A1 | ORGANIC COMPOUND, COMPOSITION, ORGANIC OPTOELECTRONIC DEVICE, AND DISPLAY DEVICE | OCIAD1, OXER1, OR10J3 | SMN1; SMN2 3621/4885CA12 573/4885CA1 1374/4885 |
| US-20200388765-A1 | ORGANIC COMPOUND, COMPOSITION, ORGANIC OPTOELECTRONIC DEVICE, AND DISPLAY APPARATUS | OCIAD1, OXER1, OR10J3 | SMN1; SMN2 3529/4885CA12 739/4885CA1 1496/4885 |
| US-10553800-B2 | Condensed cyclic compound and an organic light-emitting device including the same | CRY1, CRY2, CCNT1 | SMN1; SMN2 4074/4885CA12 1240/4885CA1 1455/4885 |
| US-20180050992-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS | MC1R, CALCRL, BDKRB2 | SMN1; SMN2 4090/4885CA12 3904/4885CA1 4370/4885 |
| US-20060241172-A1 | Benzodioxane and benzodioxolane derivatives and uses thereof | HTR2C, HTR1D, HTR1A | SMN1; SMN2 1352/4885CA12 4780/4885CA1 4027/4885 |
| US-20050038068-A1 | Thienopyridones as AMPK activators for the treatment of diabetes and obesity | PRKAG1, PRKAG3, PRKAG2 | SMN1; SMN2 4596/4885CA12 4884/4885CA1 4878/4885 |
| US-12402529-B2 | Organic compound, composition, organic optoelectronic device, and display device | OCIAD1, OXER1, OR10J3 | SMN1; SMN2 3621/4885CA12 573/4885CA1 1374/4885 |
| US-11844271-B2 | Organic compound, composition, organic optoelectronic device, and display apparatus | OCIAD1, OXER1, OR10J3 | SMN1; SMN2 3529/4885CA12 739/4885CA1 1496/4885 |
| US-10246422-B2 | Heterocyclic compounds and use thereof in medicine and in cosmetics | MC1R, BDKRB2, CCKBR | SMN1; SMN2 3905/4885CA12 3779/4885CA1 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.